Regeneron/Bayer reveal positive results for CRVO study
Regeneron Pharmaceuticals and Bayer HealthCare reveal positive results for VEGF Trap-Eye (aflibercept ophthalmic solution) in the phase III GALILEO study in patients with macular edema due to central retinal vein occlusion (CRVO).
In GALILEO, the primary endpoint at week 24 was achieved: 60.2% of patients receiving monthly VEGF Trap-Eye 2 milligrams gained at least 15 letters of vision from baseline, compared to 22.1% of patients receiving sham injections (p
The most common adverse events were those typically associated with intravitreal injections or the underlying disease. The incidence of ocular serious adverse events was higher in the sham group compared to the active treatment arm (8.8% versus 2.9%).